Patient characteristics
white matter volume, gray matter volume
SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, MAY, PMS
Between May 2017 and May 2019, 15 patients with PMS were enrolled: 12 patients received the drug product, two left the trial due to immunosuppressive therapy contraindications and one decided to spontaneously leave the trial before transplantation. The last patient last visit was performed in June 2021. Table Clinical and demographic featuresSPMS, secondary progressive multiple sclerosis; IQR, interquartile range; DMT, disease-modifying therapy; AZA, azathioprine; MTX, methotrexate; CTX, cyclophosphamide; FTY, fingolimod; RTX, rituximab; OCR, ocrelizumab; DMF, dimethyl fumarate; MRI, magnetic resonance imaging; Gd, gadolinium; nBV, normalized brain volume; nWMV, normalized white matter volume; nGMV, normalized gray matter volume; CSA, cross-sectional area; nLThalV, normalized left thalamic volume; nRThalV, normalized right thalamic volume.